Trials / Completed
CompletedNCT00141830
Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methotrexate plus ERB-041 for 12 weeks | |
| DRUG | Placebo for 12 weeks |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-10-19
- Completion
- 2006-10-19
- First posted
- 2005-09-01
- Last updated
- 2020-09-29
Locations
35 sites across 6 countries: United States, Canada, Hungary, Italy, Mexico, Spain
Source: ClinicalTrials.gov record NCT00141830. Inclusion in this directory is not an endorsement.